Catalyst Calendar

Tue, Sep 8, 2026

1 updates

4:05 PM

Protara Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference

NEW YORK, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced that management will present at the H.C.

protaratx.com

Tue, Aug 11, 2026

1 updates

TARA

8:00 AM

Protara Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update

Expect to complete enrollment of the BCG-Unresponsive registrational cohort of the ADVANCED-2 trial in 4Q 2026 The ADVANCED-3 trial is being redesigned as an exploratory trial to expand into and accelerate data in high-grade, high-risk BCG-Naïve and BCG-Exposed CIS (± Ta/T1) patients and papillary

Presentation / Abstract • Phase 2poster presentation Fri, Apr 10, 2026protaratx.com